{'fraction_non_alphanumeric': 0.014285714285714285, 'fraction_numerical': 0.0, 'mean_word_length': 5.055555555555555, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Early phase value scan for biotechnology innovation

Abstract The registration of a medicinal product by EMA or FDA used to be the main driving critical success factor for the future sales of a new medicinal product. The current additional important criteria for reimbursement decisions are cost-effectiveness and budgetary impact, which are taken into consideration in order to make a value for money decision. In order to maximize the chances of obtaining reimbursement at a maximum price, it is very important to have a well thought through strategy at the early onset of the development program in order to proactively cope with the emerging reimbursement hurdles. This paper aims to provide a pricing, market access and reimbursement strategy, which is based on a strategic scan, sales forecast model, pricing model, and cost-effectiveness model. These models are interacted and linked with a discounted cash flow model in order to optimize the economic value of the company.